A Phase 1, Open-label, Multicenter, Non-comparative Pharmacokinetics and Safety Study of Intravenous Isavuconazonium Sulfate in Pediatric Patients

Trial Profile

A Phase 1, Open-label, Multicenter, Non-comparative Pharmacokinetics and Safety Study of Intravenous Isavuconazonium Sulfate in Pediatric Patients

Recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Oct 2017

At a glance

  • Drugs Isavuconazonium (Primary)
  • Indications Haematological malignancies
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Astellas Pharma Global Development
  • Most Recent Events

    • 11 Oct 2017 Planned End Date changed from 1 Nov 2019 to 1 Dec 2019.
    • 11 Oct 2017 Planned primary completion date changed from 1 Nov 2019 to 1 Dec 2019.
    • 14 Sep 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top